Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis

Journal of Diabetes Investigation

Volumn 8, Issue 4, 2017, Pages 510-517

  Cai, Xiaoling ^a   Ji, Liwei ^b   Chen, Yifei ^a   Yang, Wenjia ^a   Zhou, Lingli ^a   Han, Xueyao ^a   Zhang, Simin ^a   Ji, Linong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Bodyweight; Glucagon like peptide 1 analogs; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

ALBIGLUTIDE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; IPRAGLIFLOZIN; LIRAGLUTIDE; LIXISENATIDE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TASPOGLUTIDE; TOFOGLIFLOZIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ARTICLE; BODY MASS; DATA EXTRACTION; DATA PROCESSING; DATA SELECTION; DIABETIC PATIENT; DISEASE DURATION; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT CHANGE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BODY WEIGHT LOSS; COMPARATIVE STUDY; DRUG EFFECTS;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; WEIGHT LOSS;

EID: 85016574223     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12625     Document Type: Article

References (35)

1. Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–1379.
2. Klein S, Sheard NF, Pi-Sunyer X. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004; 27: 2067–2073.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2015; 38(Suppl 1): S8–S16.
4. Pi-Sunyer FX. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 2008; 120: 5–17.
5. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 1997; 20: 1744–1766.
6. Lavie CJ, Milani RV, Artham SM, et al. The obesity paradox, weight loss, and coronary disease. Am J Med 2009; 122: 1106–1114.
7. Bennett WL, Maruthur NM, Singh S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602–613.
8. Bergenstal RM. Efficacy and safety of Taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-Emerge 4 trial). Diabetes Ther 2012; 3: 13.
9. Buse JB. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes. Diabetes Care 2004; 27: 2628–2635.
10. Nauck M. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. Diabetes Care 2009; 32: 84–90.
11. Meng W, Ellsworth BA, Nirschl AA. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145–1149.
12. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427–3434.
13. Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Therapy 2011; 2: 133–145.
14. Bolinder J, Ljunggren O, Kullberg J. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020–1031.
15. Cai X, Han X, Luo Y, et al. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis. J Diabetes 2015; 7: 347–359.
16. Russell-Jones D. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046–2055.
17. Seino Y. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diab Res Clin Prac 2008; 81: 161–168.
18. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127–1142.
19. Wilding JP, Hardy K. Glucagon-like peptide-1 analogues for type 2 diabetes. BMJ 2011; 342: d410.
20. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11(Suppl 3): 26–34.
21. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928–938.
22. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656–1662.
23. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217–2224.
24. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117–2128.
25. van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 784–793.
26. Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377–385.
27. Meier JJ, Gethmann A, Gotze O, et al. Glucagonlike peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006; 49: 452–458.
28. Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665–673.
29. Flint A, Raben A, Ersboll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 2001; 25: 781–792.
30. Freemantle N, Holmes J, Hockey A, et al. How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract 2008; 62: 1391–1396.
31. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133: 496–506.
32. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015; 100: 2849–2852.
33. Rosenstock J, Ferrannini E. Euglycemic diabetic Ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2Inhibitors. Diabetes Care 2015; 38: 1638–1642.
34. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 2015; 3: 8–10.
35. Kaur A, Winters SJ. Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin. Endocrinol Diabetes Metab Case Rep 2015; 2015: 150042.